Literature DB >> 16216865

B-type natriuretic peptide identifies silent myocardial ischaemia in stroke survivors.

K Y K Wong1, S McSwiggan, N S J Kennedy, R S MacWalter, A D Struthers.   

Abstract

OBJECTIVE: To test the hypothesis that B-type natriuretic peptide (BNP) predicts reversible myocardial ischaemia in stroke survivors who do not have chest pain or previous myocardial infarction.
METHODS: 56 stroke survivors (mean (SE) age 68 (8) years) underwent tetrofosmin myocardial perfusion scanning with dipyridamole as the stressor. The degree of ischaemia was assessed by a scoring system (out of 64) by an experienced observer blinded to the results of BNP.
RESULTS: In the whole cohort, BNP was significantly correlated with the degree of myocardial ischaemia on stress scanning (Spearman's r = -0.475, p < 0.001). BNP also correlated with the degree of reversible ischaemia (stress score - rest score; Spearman's r = 0.28, two tailed p = 0.049). In the cohort who did not have left ventricular systolic dysfunction (n = 44), BNP remained higher in patients with relevant myocardial ischaemia (mean (SE) BNP 20.9 pg/ml, 95% confidence interval (CI) 15.2 to 26.5 v 12.2 pg/ml, 95% CI 5.95 to 18.5; p = 0.046); 33 of the 44 patients had no chest pain or history of myocardial infarction. The relation between resting BNP and both inducible ischaemia and dipyridamole stress score remained significant (Spearman's r = 0.37 and -0.38, respectively).
CONCLUSIONS: BNP correlates with the degree of reversible myocardial ischaemia in patients who do not have chest pain or a history of myocardial infarction or evidence of left ventricular systolic dysfunction. Stroke survivors with a high BNP deserve further investigations to rule out significant reversible myocardial ischaemia, in order to reduce their risk of cardiac death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216865      PMCID: PMC1860872          DOI: 10.1136/hrt.2005.060350

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

1.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Authors:  B Pitt; D Waters; W V Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

2.  Increased cardiac BNP expression associated with myocardial ischemia.

Authors:  J P Goetze; C Christoffersen; M Perko; H Arendrup; J F Rehfeld; J Kastrup; L B Nielsen
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

3.  Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction.

Authors:  Saihari Sadanandan; Christopher P Cannon; Kasi Chekuri; Sabina A Murphy; Peter M Dibattiste; David A Morrow; James A de Lemos; Eugene Braunwald; C Michael Gibson
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

4.  N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris.

Authors:  Michael Weber; Thorsten Dill; Roman Arnold; Matthias Rau; Okan Ekinci; Klaus D Müller; Alexander Berkovitsch; Veselin Mitrovic; Christian Hamm
Journal:  Am Heart J       Date:  2004-10       Impact factor: 4.749

5.  Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion.

Authors:  William E Hopkins; Zengyi Chen; Naomi K Fukagawa; Christian Hall; Harm J Knot; Martin M LeWinter
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

6.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2004-02-12       Impact factor: 91.245

7.  Plasma brain natriuretic peptide in assessment of acute dyspnoea.

Authors:  M Davis; E Espiner; G Richards; J Billings; I Town; A Neill; C Drennan; M Richards; J Turner; T Yandle
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

  7 in total
  4 in total

1.  Additive Value of B-Type Natriuretic Peptide on Rest Tl-Dipyridamole Stress Tc-Sestamibi Gated Myocardial SPECT in Patients with Normal Left Ventricular Systolic Function.

Authors:  Jung-Ju Sir; Young-Seok Cho; Woo-Young Chung; Bon-Kwon Koo; In-Ho Chae; Dong-Ju Choi; Hyo-Soo Kim; Byung-Hee Oh; Young-Bae Park
Journal:  Cardiol Res Pract       Date:  2010-04-12       Impact factor: 1.866

2.  B-type natriuretic peptide as a marker for heart failure in patients with acute stroke.

Authors:  Matthew A Koenig; H Adrian Puttgen; Vivek Prabhakaran; Daniel Reich; Robert D Stevens
Journal:  Intensive Care Med       Date:  2007-05-31       Impact factor: 17.440

3.  N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS.

Authors:  Paul Welsh; Orla Doolin; Peter Willeit; Chris Packard; Peter Macfarlane; Stuart Cobbe; Vilmundur Gudnason; Emanuele Di Angelantonio; Ian Ford; Naveed Sattar
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

4.  The effect of percutaneous coronary revascularization on plasma N-terminal pro-B-type natriuretic peptide levels in stable coronary artery disease.

Authors:  Amit Gupta; Jahangir Rashid Beig; Nisar A Tramboo; Dil Afroze; Imran Hafeez; Hilal A Rather
Journal:  Indian Heart J       Date:  2017-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.